Literature DB >> 12644906

Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Annamaria De Luca1, Sophie Talon, Michela De Bellis, Jean-François Desaphy, Carlo Franchini, Giovanni Lentini, Alessia Catalano, Filomena Corbo, Vincenzo Tortorella, Diana Conte-Camerino.   

Abstract

In striated fibers, the activity of mexiletine (Mex)-like sodium channel blockers is strongly modulated by the part of the molecule nearby the asymmetric carbon atom. A lipophilic aromatic phenyl group at this levels, as in 2-(2,6-dimethylphenoxy)-1-phenylethanamine (Me4), markedly increases drug potency, while an increased distance between the stereogenic center and the pharmacophore amino group, as in 3-(2,6-dimethylphenoxy)-2-methylpropan-1-amine (Me2), enhances the use-dependent behavior. In order to better evaluate the role of lipophilicity in drug potency in relation to the structural determinants for a specific binding, lipophilic analogs of Me2 and Me4 were synthesized. Compounds 3-[(2,6-dimethylphenyl)thio]-2-methylpropan-1-amine and 2-[(2,6-dimethylphenyl)thio]-1-phenylethanamine were obtained by isosteric substitution of the oxygen atom with sulfur, while the introduction of a chlorine atom in 4- position of the aryloxy ring lead to 3-(4-chloro-2,6-dimethylphenoxy)-2-methylpropan-1-amine and 2-(4-chloro-2,6-dimethylphenoxy)-1-phenylethanamine. The compounds were tested on nearly maximal Na(+) currents elicited with depolarizing steps at 0.3 Hz (tonic block) and 2-10 Hz (use-dependent block) by means of vaseline-gap voltage-clamp method on single frog muscle fibers.The augmented lipophilicity largely increase drug potency in Me2 analogues, the thio and chlorinated compounds being 20- and 10-fold more potent in producing the tonic block, respectively. However, both compounds showed a 2-fold lower use-dependent behavior vs. the high use-dependent Me2. Surprisingly, the same increase in lipophilicity brought about by the same substitutions, in the already high lipophilic and potent Me4 failed to further improve the potency, although both new analogs were more stereoselective than Me4. No correlation was found between logP and potency of all analogs tested. All compounds acted as inactivated channel blockers. In conclusion, lipophilicity differently influences drug profile based on the molecular determinants controlling drug-receptor interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644906     DOI: 10.1007/s00210-002-0669-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  An improved vaseline gap voltage clamp for skeletal muscle fibers.

Authors:  B Hille; D T Campbell
Journal:  J Gen Physiol       Date:  1976-03       Impact factor: 4.086

2.  Cardiac-specific external paths for lidocaine, defined by isoform-specific residues, accelerate recovery from use-dependent block.

Authors:  P J Lee; A Sunami; H A Fozzard
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

3.  Lipophilicity and membrane interactions of cationic-amphiphilic compounds: syntheses and structure-property relationships.

Authors:  C D Klein; G F Tabeteh; A V Laguna; U Holzgrabe; K Mohr
Journal:  Eur J Pharm Sci       Date:  2001-09       Impact factor: 4.384

4.  Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na(+) channels with increased potency and improved use-dependent activity.

Authors:  C Franchini; F Corbo; G Lentini; G Bruno; A Scilimati; V Tortorella; D Conte Camerino; A De Luca
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

5.  Effects of log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel.

Authors:  M L Brown; G B Brown; W J Brouillette
Journal:  J Med Chem       Date:  1997-02-14       Impact factor: 7.446

6.  Sodium channel blockers: the size/solubility hypothesis revisited.

Authors:  K R Courtney
Journal:  Mol Pharmacol       Date:  1990-06       Impact factor: 4.436

7.  Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.

Authors:  A De Luca; F Natuzzi; J F Desaphy; G Loni; G Lentini; C Franchini; V Tortorella; D C Camerino
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

8.  Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels.

Authors:  C C Kuo; R C Huang; B S Lou
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

9.  Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels.

Authors:  A Duranti; C Franchini; G Lentini; F Loiodice; V Tortorella; A De Luca; S Pierno; D Conte Camerino
Journal:  Eur J Med Chem       Date:  2000-01       Impact factor: 6.514

10.  Point mutations at N434 in D1-S6 of mu1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers.

Authors:  C Nau; S Y Wang; G R Strichartz; G K Wang
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

View more
  6 in total

1.  Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents.

Authors:  M De Bellis; A De Luca; F Rana; M M Cavalluzzi; A Catalano; G Lentini; C Franchini; V Tortorella; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

2.  Molecular Insights into the Local Anesthetic Receptor within Voltage-Gated Sodium Channels Using Hydroxylated Analogs of Mexiletine.

Authors:  Jean-François Desaphy; Antonella Dipalma; Teresa Costanza; Roberta Carbonara; Maria Maddalena Dinardo; Alessia Catalano; Alessia Carocci; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Front Pharmacol       Date:  2012-02-15       Impact factor: 5.810

3.  Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Authors:  Michela De Bellis; Annamaria De Luca; Jean F Desaphy; Roberta Carbonara; Judith A Heiny; Ann Kennedy; Alessia Carocci; Maria M Cavalluzzi; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Biophys J       Date:  2013-01-22       Impact factor: 4.033

4.  Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

Authors:  Michela De Bellis; Roberta Carbonara; Julien Roussel; Alessandro Farinato; Ada Massari; Sabata Pierno; Marilena Muraglia; Filomena Corbo; Carlo Franchini; Maria Rosaria Carratù; Annamaria De Luca; Diana Conte Camerino; Jean-François Desaphy
Journal:  Neuropharmacology       Date:  2016-10-13       Impact factor: 5.250

5.  Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.

Authors:  Michela De Bellis; Francesca Sanarica; Alessia Carocci; Giovanni Lentini; Sabata Pierno; Jean-François Rolland; Diana Conte Camerino; Annamaria De Luca
Journal:  Front Pharmacol       Date:  2018-01-12       Impact factor: 5.810

Review 6.  KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.